Nektar Therapeutics reports developments as a clinical-stage biotechnology company developing immunology therapies for autoimmune and chronic inflammatory diseases. Company news centers on rezpegaldesleukin, also known as REZPEG or NKTR-358, a regulatory T cell stimulator evaluated across disease areas including atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus.
Recurring updates also cover Nektar's preclinical pipeline, including TNFR2 antibody and bispecific programs NKTR-0165 and NKTR-0166, and the modified hematopoietic colony stimulating factor protein NKTR-422. Financial results, public equity offerings, shelf-registration activity, employee inducement grants, and other capital and governance actions are regular news themes for NKTR.
Nektar Therapeutics (Nasdaq: NKTR) priced an upsized public offering to raise approximately $400 million by selling 6,603,449 common shares and 293,103 pre-funded warrants at $58.00 (or $57.9999 for warrants) per unit.
The offering may close on February 13, 2026, includes a 30-day underwriter option for up to 1,034,482 additional shares, and intends net proceeds for general corporate purposes, including Phase 3 rezpegaldesleukin development and manufacturing.
Nektar Therapeutics (Nasdaq: NKTR) on Feb. 10, 2026 announced a proposed underwritten public offering of $300,000,000 of common stock and, for certain investors, pre-funded warrants, with a 30-day option for up to an additional $45,000,000. The offering is subject to market conditions.
Proceeds are intended for general corporate purposes, including research and development, clinical development (including Phase 3 trials for rezpegaldesleukin), and manufacturing. Jefferies, TD Cowen, and Piper Sandler are joint bookrunning managers. The securities will be offered under a Form S-3ASR shelf registration that became effective Nov. 12, 2025.
Nektar Therapeutics (Nasdaq: NKTR) reported 36-week blinded maintenance results from the 52-week REZOLVE-AD Phase 2b study of rezpegaldesleukin in moderate-to-severe atopic dermatitis.
Key findings: durable EASI-75/EASI-90 and vIGA-AD 0/1 maintenance with 24 µg/kg Q4W and Q12W, up to 5-fold increases in EASI-100 during maintenance, favorable safety with 3.5% discontinuation for adverse events, and plan to advance to Phase 3 with a target BLA submission in 2029.
Nektar (Nasdaq: NKTR) will host an investor call and live webcast on February 10, 2026 at 8:00 am ET to review topline results from the 36‑week maintenance period of the Phase 2b REZOLVE-AD study of rezpegaldesleukin in moderate-to-severe atopic dermatitis.
According to the company, a morning press release will publish the results, slides will be posted on the Nektar investor events page, and a replay will be available for at least 30 days.
Nektar Therapeutics (NASDAQ: NKTR) announced that on January 21, 2026 its Organization and Compensation Committee granted non-qualified stock options to purchase 1,600 shares to one newly hired employee under the 2025 Inducement Plan.
The options have an exercise price of $36.92 (closing price on January 21, 2026), an eight-year term, and vest over four years (25% after one year, then monthly 1/48ths).
Nektar Therapeutics (Nasdaq: NKTR) reported topline 36-week results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin in 92 patients with severe-to-very-severe alopecia areata. Both dose arms showed mean SALT score reductions of 28.2% (24 µg/kg) and 30.3% (18 µg/kg) versus 11.2% for placebo; the primary endpoint narrowly missed statistical significance in the mITT population. Excluding four patients with major eligibility violations, the primary endpoint reached significance (29.6% and 30.4% vs 5.7%, p=0.049 and p=0.042). Key secondary outcomes (SALT30, SALT≤30/20/10) favored treatment. Safety was described as well tolerated with mostly mild-to-moderate TEAEs and a 1.4% discontinuation rate in treatment arms. Nektar plans to advance rezpegaldesleukin to Phase 3 in 2026 and will present additional data in 2026.
Nektar (Nasdaq: NKTR) will host an investor conference call and live webcast to review topline 36-week induction results from the ongoing Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin for severe-to-very-severe alopecia areata.
The event is scheduled for December 16, 2025 at 8:00 AM ET / 5:00 AM PT. Results will be released in a morning press release and presented on the webcast; slides and the press release will be posted in the company's events section at https://ir.nektar.com/events-and-presentations/events. A replay will be available for at least 30 days after the event.
Nektar Therapeutics (NASDAQ:NKTR) announced inducement grants under Nasdaq Listing Rule 5635(c)(4) for two newly hired employees totaling 18,310 non-qualified stock options under Nektar's 2025 Inducement Plan.
Grant details: 7,260 options granted on Nov 25, 2025 at an exercise price of $60.35 (closing price that day), and 11,050 options granted on Dec 4, 2025 at an exercise price of $57.69 (closing price that day). Options have an 8-year term and vest over 4 years with 1/4 vesting after one year and the remainder vesting monthly over the next three years, subject to continued employment and plan/option agreement terms.
Nektar Therapeutics (Nasdaq: NKTR) presented new REZOLVE-AD Phase 2b data at ACAAI on Nov 8, 2025 showing statistically significant, clinically meaningful improvements in asthma control and atopic dermatitis endpoints with rezpegaldesleukin.
In 99 patients with AD and asthma, mean ACQ-5 scores improved at Week 16 versus placebo (two dose arms p<0.05); placebo worsened. In patients with baseline ACQ-5 ≥0.5 (N=53) placebo-adjusted ACQ-5 reductions ranged 0.7–1.0; in uncontrolled asthma (N=25) reductions ranged 1.0–1.4. Rezpegaldesleukin 24 μg/kg q2w met primary and key secondary AD endpoints (EASI, EASI-75, EASI-90, vIGA-AD, itch) at Week 16 and supports a 24-week induction for Phase 3.
Nektar Therapeutics (Nasdaq: NKTR) reported third-quarter 2025 results for the period ended September 30, 2025. Cash and marketable securities were $270.2M (includes July secondary offering net proceeds and ATM proceeds); company expects cash to support operations into Q2 2027. Revenue was $11.8M in Q3 2025 versus $24.1M in Q3 2024, reflecting the December 2024 sale of the Huntsville manufacturing facility. R&D expense was $27.3M in Q3; Net loss was $35.5M ($1.87 per share) in Q3 and $128.0M year-to-date.
Key clinical and corporate items: REZOLVE-AD data presented at EADV and ACAAI; FDA granted Fast Track for rezpegaldesleukin in severe-to-very-severe alopecia areata; company raised capital including a $115M gross public offering and ATM proceeds.